Skip to main content
Journal cover image

Gadolinium-based contrast agents: A comprehensive risk assessment.

Publication ,  Journal Article
Fraum, TJ; Ludwig, DR; Bashir, MR; Fowler, KJ
Published in: J Magn Reson Imaging
August 2017

UNLABELLED: Gadolinium-based contrast agents (GBCAs) have been used in magnetic resonance imaging (MRI) since the 1980s and are now administered in up to 35% of all MRI examinations. While GBCAs were initially felt to carry minimal risk, the subsequent identification of GBCAs as the key etiologic factor in the development of nephrogenic systemic fibrosis (NSF) has raised concerns about the broader health impacts of gadolinium exposure. Clinicians, radiologists, and patients should be aware of the most up-to-date data pertaining to the risks of GBCA administration. Specific issues covered in this review article include immediate adverse reactions; pregnancy and lactation; and gadolinium deposition and toxicity, with a special focus on NSF. Practice recommendations based on the presented data, as well as current professional society guidelines, are provided for each section. LEVEL OF EVIDENCE: 1 Technical Efficacy: Stage 5 J. MAGN. RESON. IMAGING 2017;46:338-353.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Magn Reson Imaging

DOI

EISSN

1522-2586

Publication Date

August 2017

Volume

46

Issue

2

Start / End Page

338 / 353

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Tissue Distribution
  • Risk Factors
  • Risk Assessment
  • Pregnancy
  • Nuclear Medicine & Medical Imaging
  • Nephrogenic Fibrosing Dermopathy
  • Maternal Exposure
  • Magnetic Resonance Imaging
  • Lactation
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Fraum, T. J., Ludwig, D. R., Bashir, M. R., & Fowler, K. J. (2017). Gadolinium-based contrast agents: A comprehensive risk assessment. J Magn Reson Imaging, 46(2), 338–353. https://doi.org/10.1002/jmri.25625
Fraum, Tyler J., Daniel R. Ludwig, Mustafa R. Bashir, and Kathryn J. Fowler. “Gadolinium-based contrast agents: A comprehensive risk assessment.J Magn Reson Imaging 46, no. 2 (August 2017): 338–53. https://doi.org/10.1002/jmri.25625.
Fraum TJ, Ludwig DR, Bashir MR, Fowler KJ. Gadolinium-based contrast agents: A comprehensive risk assessment. J Magn Reson Imaging. 2017 Aug;46(2):338–53.
Fraum, Tyler J., et al. “Gadolinium-based contrast agents: A comprehensive risk assessment.J Magn Reson Imaging, vol. 46, no. 2, Aug. 2017, pp. 338–53. Pubmed, doi:10.1002/jmri.25625.
Fraum TJ, Ludwig DR, Bashir MR, Fowler KJ. Gadolinium-based contrast agents: A comprehensive risk assessment. J Magn Reson Imaging. 2017 Aug;46(2):338–353.
Journal cover image

Published In

J Magn Reson Imaging

DOI

EISSN

1522-2586

Publication Date

August 2017

Volume

46

Issue

2

Start / End Page

338 / 353

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Tissue Distribution
  • Risk Factors
  • Risk Assessment
  • Pregnancy
  • Nuclear Medicine & Medical Imaging
  • Nephrogenic Fibrosing Dermopathy
  • Maternal Exposure
  • Magnetic Resonance Imaging
  • Lactation